Clinical trial · Observational
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for Recurrent and/or Metastatic Nasopharyngeal Carcinoma
NCT06197776CI-TRIAL-00111023recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The observational clinical study will recruit 50 recurrent and/or metastatic nasopharyngeal carcinoma (r/mNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined with immunotherapy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Efficacy of Chemoradiotherapy and Immunotherapy | — | UNRESOLVED | — |
| Multi-omics Technique | — | UNRESOLVED | — |
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Recurrent and Metastatic Nasopharyngeal Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin-based chemoradiotherapy combined with immunotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- chemoradiotherapy combined with immunotherapy
- description
- Patients treated with chemoradiotherapy combined with immunotherapy
- interventionNames
- Drug: cisplatin-based chemoradiotherapy combined with immunotherapy
Primary outcomes (1)
- measure
- Failure-free survival
- timeFrame
- 3 years
- description
- To investigate the multi-omics technique to predict the 3-year failure-free survival of chemoradiotherapy combined with immunotherapy for r/m NPC patients
Secondary outcomes (3)
- measure
- ctDNA
- timeFrame
- through study completion, an average of 6 months
- description
- To show the changes of ctDNA during the treatment among these patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Recurrent or metastatic nasopharyngeal carcinoma patients * All genders，range from 18～70 years old * ECOG score 0 \~ 1 * Inform consent form Exclusion Criteria: * Have or are suffering from other malignant tumors; * Participating in other clinical trials; * Drug or alcohol addition; * Do not have full capacity for civil acts; * Mental disorder; * Pregnancy or lactation; * Severe complication, eg, uncontrolled hypertension.
References
Publications (0)
Data not yet available
No reference posted for this study.